You have free access to this content

Progressive anemia following combination therapy with interferon-α and interleukin-2 in a patient with metastatic renal cell carcinoma

YUKINARI HOSOKAWA^1,*,
TATSUKI KISHINO¹,
TAKAMASA ONO¹,
NOBUO OYAMA¹,
KUNIO HAYASHI²,
HITOSHI MOMOSE¹

Article first published online: 12 OCT 2004

DOI: 10.1111/j.1442-2042.2004.00914.x

Issue

International Journal of Urology

Volume 11, Issue 10, pages 906–908, October 2004

Additional Information

How to Cite

HOSOKAWA, Y., KISHINO, T., ONO, T., OYAMA, N., HAYASHI, K. and MOMOSE, H. (2004), Progressive anemia following combination therapy with interferon-α and interleukin-2 in a patient with metastatic renal cell carcinoma. International Journal of Urology, 11: 906–908. doi: 10.1111/j.1442-2042.2004.00914.x

Author Information

¹
Departments of Urology and
²
Hematology, Hoshigaoka Koseinenkin Hospital, Osaka, Japan

^*Yukinari Hosokawa md, Department of Urology, Hoshigaoka Koseinenkin Hospital, 4-8-1 Hoshigaoka, Hirakata, Osaka 573-8511, Japan. Email: yukinari46@nyc.odn.ne.jp

Publication History

Issue published online: 12 OCT 2004
Article first published online: 12 OCT 2004
Received 26 May 2003; accepted 16 March 2004.

ARTICLE TOOLS

View Full Article (HTML) Get PDF (199K)

References

1
Motzer RJ, Bander NH, Namus DM. Renal cell carcinoma. N. Engl. J. Med. 1996; 335: 865–75.
2
Negrier S, Escudier B, Lasset C et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. N. Engl. J. Med. 1998; 338: 1272–8.
3
Pizzocaro G, Piva L, Colavita M et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J. Clin. Oncol. 2001; 19: 425–31.
4
Buzio C, Andrulli S, Santi R et al. Long-term immunotherapy with low-dose interleukin-2 and interferon-α in the treatment of patients with advanced renal cell carcinoma. Cancer 2001; 92: 2286–96.
Direct Link:
5
Dutcher JP, Atkins M, Fisher R et al. Interleukin-2 based therapy for metastatic renal cell cancer: The cytokine Working Group experience, 1989–97. Cancer J. Sci. Am. 1997; 3: S73–S78.
- PubMed,
- Web of Science® Times Cited: 42
6
Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N. Engl. J. Med. 1988; 318: 1557–63.
7
Whitehead RP, Hauschild A, Christophers E, Figlin R. Diabetes mellitus in cancer patients treated with combination interleukin-2 and α-interferon. Cancer Biotherapy 1995; 10: 45–51.
8
Perez R, Padavic K, Krigel R, Weiner L. Antierythrocyte autoantibody formation after therapy with interleukin-2 and gamma-interferon. Cancer 1991; 67: 2512–17.
Direct Link:
9
Ettinghausen S, Moore JG, White DE, Platanias L, Young NS, Rosenberg SA. Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Blood 1987; 69: 1654–60.
10
Chabot GG, Flaherty LE, Validivieso M, Baker LH. Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients. Cancer Chemother. Pharmacol. 1990; 27: 157–60.

View Full Article (HTML) Get PDF (199K)

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Progressive anemia following combination therapy with interferon-α and interleukin-2 in a patient with metastatic renal cell carcinoma

International Journal of Urology

How to Cite

Author Information

Publication History

ARTICLE TOOLS

References

More content like this

JOURNAL TOOLS

JOURNAL MENU

FIND ISSUES

FIND ARTICLES

GET ACCESS

FOR CONTRIBUTORS

ABOUT THIS JOURNAL

SPECIAL FEATURES

Progressive anemia following combination therapy with interferon-α and interleukin-2 in a patient with metastatic renal cell carcinoma

International Journal of Urology

How to Cite

Author Information

Publication History

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

References

More content like this